Prevalence of NS3 Mutations Inducing Resistance to Protease Inhibitors in Chronically Infected Hepatitis C Virus Genotype 4 Patients in Egypt
Ahmed Gaballah, Iman Naga, Amel Elsheredy, Gamal Elsawaf & Ola Kader · Microbiology Research Journal International · 2018
Background and Objectives: Directly acting antiviral agents, like NS3 protease inhibitors, are representing the backbone for the current therapy of Hepatitis C virus infection. Given the heterogeneities in HCV genome, not all protease inhibitors will be equally effective against...
Open access
Research Article
10.9734/MRJI/2018/40180